Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Rhenium NanoLiposome for recurrent glioblastoma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):